Skip to main content

Table 2 Protective efficacy of recombinant VLP vaccine against challenge with vvIBDV in 3-week-old SPF chickens compared with a commercial inactivated vaccine or no vaccine (PBS treatment). Two weeks after immunization, birds were challenged with vvIBDV LC10 strain orally (104.5EID50 per bird) and observed for 10 days

From: Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4

Vaccine Mortality, n (%) Clinical signs, na Gross lesions, nb Bursal atrophy, nc B/BW ratio, mean (SD)
Inactivated vaccine (n = 12) 0 (0)** 0*** 3** 3** 3.46 (1.42)*
VLP vaccine (n = 12) 0 (0)** 0*** 4* 3** 3.69 (1.74)**
Control (n = 12) 7 (58) 12 5 5 1.14 (0.30)
  1. aNumber of birds with clinical signs, including depression, anorexia, diarrhea, and death
  2. bNumber of surviving birds with gross lesions in the BF
  3. cNumber of surviving animals with a B/BW ratio (bursal weight/body weight x 1000) lower than 2
  4. *P < 0.1, ** P <0.01, *** P <0.001 compared with the non-vaccinated control group (Fisher’s exact test)